There were 174 press releases posted in the last 24 hours and 453,224 in the last 365 days.

Agile Therapeutics to Present at Biotech Showcase 2017

Presentation Scheduled on Monday, January 9, 2017 at 9:00 AM Pacific Time

PRINCETON, N.J., Dec. 22, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) announced today that its Chief Executive Officer, Al Altomari will present at the Biotech Showcase 2017 on Monday, January 9, 2017 at 9:00 AM Pacific Time.   The conference will be held at the Hilton San Francisco Union Square.

To access the live and archived webcasts of the presentation, visit the Investor Relations section of Agile Therapeutics website at www.agiletherapeutics.com. The webcast will be archived on Agile Therapeutics website for 60 days following the event.

About Agile
Agile Therapeutics is a women’s health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products. Our product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adherence and patient acceptability.  For more information, please visit the company website at www.agiletherapeutics.com.

                                                                   

Contact: Mary Coleman 609-356-1921

Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.